论文部分内容阅读
目的研究麦比麸对羟苯磺酸钙在Beagle犬体内药物动力学的影响。方法将6只Beagle犬随机分成2组,采用随机、自身对照双周期交叉单剂量给药方式,以已确证的RP-HPLC法测定Beagle犬血浆中羟苯磺酸的浓度。采用DAS 2.1.1软件按照房室模型进行药动学参数计算,并对药物动力学参数进行统计分析。结果对照组和试验组羟苯磺酸的主要药物动力学参数如下:ρmax分别为(28.6±5.8)和(30.8±6.1)mg·L-1,tmax分别为(1.8±0.3)和(2.0±0.0)h,AUC(0→t)分别为(105.0±26.0)和(103.3±30.3)mg·L-1·h,AUC(0→∞)分别为(107.1±25.8)和(104.2±30.8)mg·L-1·h,t1/2α均为(0.9±0.5)h,t1/2β分别为(2.3±1.3)和(1.3±0.4)h,V1/F为(0.23±0.10)和(0.23±0.15)L·kg-1,Cl/F为(0.25±0.06)和(0.26±0.07)L·h-1·kg-1。上述2组药动学参数经统计学分析没有显著性差异(P>0.05)。结论麦比麸颗粒对Beagle犬口服羟苯磺酸钙胶囊后羟苯磺酸在体内的药物动力学行为无影响。
Objective To study the effect of topiramate on the pharmacokinetics of calcium dobesilate in Beagle dogs. Methods Six Beagle dogs were randomly divided into two groups. Randomized, self-controlled double-cycle crossover single-dose administration was used to determine the concentration of oxybenzene sulfonic acid in beagle dogs plasma with a validated RP-HPLC method. Pharmacokinetic parameters were calculated according to atrioventricular model using DAS 2.1.1 software, and statistical analysis of pharmacokinetic parameters was performed. Results The main pharmacokinetic parameters of oxybenzene sulfonic acid in control group and experimental group were as follows: ρmax were (28.6 ± 5.8) and (30.8 ± 6.1) mg · L-1, respectively, tmax was (1.8 ± 0.3) and 0.010) h and AUC (0 → t) were (105.0 ± 26.0) and (103.3 ± 30.3) mg · L-1 · h and AUC (0 → ∞) were (107.1 ± 25.8) and (104.2 ± 30.8) (0.9 ± 0.5) h for t1 / 2α and (2.3 ± 1.3) and (1.3 ± 0.4) h for t1 / 2β and (0.23 ± 0.10) and ± 0.15) L · kg-1, Cl / F was (0.25 ± 0.06) and (0.26 ± 0.07) L · h-1 · kg-1. The above two groups of pharmacokinetic parameters by statistical analysis showed no significant difference (P> 0.05). Conclusion: Maobeibi granule has no effect on the pharmacokinetics of oxybenzene sulfonic acid in Beagle dogs after oral administration of calcium dobesilate capsules.